Skip to main content
Department of Internal Medicine

Department of Internal Medicine

Appointments & Referrals

Monday-Friday:
8 a.m. to 5 p.m.
Physician Referral Center
Specialty referrals
and phone consultations:
1-800-4-UCDAVIS
1-800-482-3284
(choose option #2)
Consumer Resource Center
1-800-2-UCDAVIS
1-800-282-3284
General information
Cardiovascular medicine:
916-734-3761

Clinical Trials

Cardiovascular medicine

Physician training

News

More news...

Cardiovascular Clinical Research Unit

Director: Reginald Low, M.D.
Administrator: Kori Harder 

The Cardiovascular Clinical Research Unit in Sacramento conducts clinical trials in conjunction with various pharmaceutical companies and members of our clinical faculty. Several primary investigators on our faculty also oversee laboratory research on the UC Davis campus.

This research unit performs Phase I, II, III and IV clinical trials studying both drugs and medical devices. Protocols for these studies are approved for testing by the Federal Drug Administration and examined for ethical consideration by the UC Davis Human Subject Review Committee. The contractual arrangements for these studies are reviewed and approved by the Office of Research at UC Davis.

The Cardiovascular Clinical Research Unit has over ten years of experience in all areas of cardiology, including congestive heart failure, unstable angina, hypertension, hyperlipidemia, electrophysiology and myocardial infarction. The current studies include investigations of:

  • Interventional devices for patients with coronary artery disease
  • New compounds for the treatment of all aspects of heart disease, including: disturbances in cardiac rhythm, hypertension and acute coronary thrombosis

 

For information, please call 916-703-7073.

Current trials

OSIRIS – Double-blind placebo controlled study to evaluate safety and efficacy of IV infusion of adult mesenchymal stem cells following first acute myocardial infarction.

SAPPHIRE – Carotid artery stenting registry using Cordis stent and embolic capture for high-surgical-risk patients.

ZEN – Treatment of erectile dysfunction in subjects with a sub-optimal response to PDE5i therapy due to atherosclerotic lesions of the hypogastric and/or internal pudendal arteries.   

ALERTS – Implanted Guardian system to detect electrogram changes related to ACS events in subjects high-risk for recurrent myocardial infarction.

DUAL ENERGY KIDNEY CT POST PCI – Dual energy non-contrast CT done of kidneys 18-30 hours post PCI to detect potential acute renal injury after cardiac catheterization.

EVEREST II / REALISM – Percutaneous mitral valve repair versus surgical mitral valve repair or replacement in patients with 3+ or 4+ chronic mitral regurgitation.

TRILOGY ACS - To test the hypothesis that prasugrel and aspirin are superior to clopidogrel and aspirin in the treatment of medically managed subjects.

RESIST PAD – To test aspirin and Plavix non-responsiveness on outcomes in peripheral arterial disease using the Accumetrics VerifyNow device.

CHAMPION PHOENIX – Comparison of cangrelor to clopidogrel standard of care therapy in subjects requiring percutaneous coronary intervention.